Table 2 Demographic and clinical characteristics of the patients receiving carbapenem treatment
From: Evaluation of carbapenem use in a tertiary hospital: antimicrobial stewardship urgently needed
Characteristic | 2010 | 2011–2013 | 2014–2016 | 2017 |
|---|---|---|---|---|
Patients N | 209 | 440 | 787 | 338 |
Male sex N (%) | 132 (63.2) | 272 (61.8) | 285 (36.2) | 127 (37.6) |
Age (years) | 60 (46–72) | 58 (45–70) | 57 (46–69) | 58 (42–67) * |
Department of Medicine (%) a | 119 (56.9) | 242 (55.0) | 430 (54.6) | 203 (60.1) |
duration of stay in the hospital | 21 (13–30) | 22 (14–33) | 18 (11–27) *# | 19 (12–28) # |
eGFR b (ml·min−1) | 91.9 (65.8–105.7) | 99.5 * (75.2–115.2) | 101.8* (80.0-118.2) | 98.65*† (64.8–113.2) |
Carbapenem duration (days) | 7 (5–11) | 8 (5–12) * | 8 (6–12) * | 8 (5–12) |
Total drug costs ($) | 3713.9 (2121.0–6489.0) | 5728.9 * (3104.0–9054.3) | 4931.2 * (2781.1–8900.5) | 5315.3 * (2521.4–10,418.6) |
Hospital costs ($) | 6254.8 (3424.7–10,819.4) | 10,130.9 * (5391.9–16,961.9) | 8929.2 * (4796.9–17,886.1) | 10,427.0 *† (4752.2–20,489.7) |